Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the current treatment landscape for the patients with myelofibrosis (MF) and how this evolved over the last decade.
For a long time, Kuykendall says the only FDA-approved therapy for the treatment of patients with MF was ruxolitinib (Jakafi). Physicians relied on this therapy for almost a decade to treat disease-related symptoms and symptoms related to the spleen.
However, in August 2019, the FDA granted approval to fedratinib (Inrebic). Fedratinib is now available as treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia MF. Kuykendall says physicians have been waiting a long time for a new therapy to become approved in the setting of patients with MF.
<< For more on the FDA approval of fedratinib in myelofibrosis
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More